Finerenone (Kerendia, BAY948862) Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Finerenone (Kerendia, BAY948862) comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Diabetes Mellitus, Type 2. Most recent publication: Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study., J Comp Eff Res, 2023.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study.
    Vizcaya D, Kovesdy CP, Reyes A, et al. · J Comp Eff Res · 2023
    PubMed: PMID 37387399 · NCT05703880 (FIRST-2) · Diabetes Mellitus, Type 2

Publications by year

2023–2023: 1 publications.

2023
1

Publications by indication

Diabetes Mellitus, Type 2 (1)

  • Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study.
    J Comp Eff Res · 2023 · PMID 37387399 · NCT05703880

Publications by journal

  • J Comp Eff Res1 paper

All Finerenone (Kerendia, BAY948862) publications (1)

2023 (1 paper)

  1. Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study.
    Vizcaya D, Kovesdy CP, Reyes A, et al. · J Comp Eff Res · 2023 · Derived
    PubMed: PMID 37387399 · NCT05703880 (FIRST-2) · Diabetes Mellitus, Type 2

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Wed, 27 May 2026 18:58:55 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).